• HOBt for High-Fidelity Amide Bond Formation

  2026-09-04

  HOBt supports efficient, mild amide bond formation when stereochemical fidelity and substrate compatibility matter. This applied guide connects coupling optimization with peptide synthesis, medicinal chemistry workflows, and the indazole-based glucagon receptor antagonist study.

• Laminin (925-933) for ECM Migration Assays

  2026-09-03

  Laminin (925-933) is a defined Laminin B1 chain peptide for separating receptor-driven adhesion and chemotaxis from the complexity of full-length ECM. Its documented activity in HT-1080, CHO, and B16F10 models also makes it a practical control or perturbation tool for basement membrane protein research and engineered organoid matrices.

• Guanabenz Acetate: Assay Design for α2 Signaling

  2026-09-03

  Guanabenz Acetate can serve as a precise α2-adrenergic receptor agonist for separating receptor-proximal signaling from downstream stress and innate-immune phenotypes. This article translates recent GADD34–stress-granule findings into a rigorous, hypothesis-driven assay framework while clearly defining what remains unproven.

• PDGF-BB in Pulmonary Vascular Remodeling Assays

  2026-09-02

  Use PDGF-BB, murine recombinant PDGF-BB as a defined mitogenic input for dose-response, receptor-signaling, and pulmonary vascular remodeling experiments. This workflow extends conventional proliferation testing into hypoxia, lactate metabolism, ALDOB lactylation, and mitochondrial phenotyping while preserving clear controls and troubleshooting checkpoints.

• GLI2–PRDX1 Ferroptosis Resistance in Bladder Cancer

  2026-09-02

  The reference study identifies a GLI2–PRDX1 transcriptional axis that suppresses ferroptosis and supports malignant progression in bladder cancer. Its combination of public-data analysis, RNA sequencing, chromatin immunoprecipitation, genetic perturbation, and rescue experiments suggests that GLI2 inhibition may improve responses to PRDX1-directed treatments and cisplatin.

• HOBt in Amide Bond Formation: A Mechanistic Guide

  2026-09-01

  Explore how HOBt (1-Hydroxybenzotriazole) controls activated ester chemistry, supports stereochemically reliable peptide synthesis, and enabled a key amide-forming step in glucagon receptor antagonist discovery. This guide connects reagent selection, hydrate-aware handling, and medicinal chemistry decision-making.

• Protease Inhibitor Cocktail: EDTA-Free Workflow

  2026-09-01

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic damage during cell lysis, protein extraction, and protease-sensitive downstream assays. It is suited to workflows requiring divalent cations, but it should not be treated as a universal inhibitor system or as a replacement for rapid, cold sample handling and separately validated phosphatase control.

• Cy3 NHS ester (non-sulfonated): Practical Guide

  2026-08-31

  Cy3 NHS ester (non-sulfonated) provides an orange fluorescent, amine-reactive labeling option for proteins, peptides, oligonucleotides, and DNA. It is suitable when a DMSO, DMF, or other compatible organic co-solvent is acceptable, but it is a poor choice for strictly aqueous workflows or long-term storage of prepared solutions.

• Guanabenz Acetate in Cell Assay Design

  2026-08-31

  Learn how Guanabenz Acetate (SKU B1335) can be integrated into cell viability, proliferation, cytotoxicity, and receptor-signaling workflows without confusing pathway effects with assay artifacts. This scenario-based guide covers solubility, stock preparation, experimental controls, literature boundaries, and vendor-selection criteria.

• HOBt for Precise Amide Bond Formation

  2026-08-30

  HOBt supports high-fidelity amide bond formation across peptide synthesis and medicinal chemistry, with particular value when stereochemical integrity and mild activation are priorities. This guide translates the reagent’s mechanism and a glucagon receptor antagonist synthesis into executable workflows, assay choices, and troubleshooting steps.

• PLAC1 Targeting in Clear Cell Renal Cell Carcinoma

  2026-08-29

  A 2025 study identifies PLAC1 as an overexpressed, prognostically unfavorable factor in clear cell renal cell carcinoma and combines patient-data analysis, molecular validation, gene knockdown, and high-throughput virtual screening. The findings nominate Amaronol B and canagliflozin as experimental compounds that reduce PLAC1-associated ccRCC progression, while also defining important questions about target specificity and clinical translation.

• SB-3CT and MMP9: Translating ECM Control

  2026-08-28

  A translational analysis of SB-3CT as a selective gelatinase inhibitor for testing MMP-2 and MMP-9 biology across perineuronal-net, tumor metastasis, and cerebral ischemia models, with practical guidance on assay design, evidence boundaries, and research strategy.

• Bestatin-Derived Inhibitors of IRAP and ERAP1

  2026-08-28

  This study develops a stereoselective route to α-hydroxy-β-amino acid derivatives of bestatin and applies it to selective inhibition of oxytocinase-family M1 aminopeptidases. Structural analysis, biochemical testing, and cell-based evaluation identify a low-nanomolar IRAP inhibitor and implicate GAMEN-loop interactions as an important source of potency and selectivity.

• HOBt for Peptide and Amide Bond Synthesis

  2026-08-27

  HOBt supports high-fidelity amide bond formation when stereochemical control and mild reaction conditions matter. This workflow-focused guide connects its use in peptide synthesis with the EDC-mediated construction of indazole glucagon receptor antagonists, including practical optimization and troubleshooting strategies.

• Novel Ziprasidone Impurity: Structure and Significance

  2026-08-27

  The reference study identified and structurally characterized a previously unreported methylene ziprasidone dimer that appeared during scale-up of ziprasidone hydrochloride manufacture. By combining preparative HPLC with high-resolution mass spectrometry and multidimensional NMR, the authors established the impurity structure and proposed a plausible formation pathway, providing a practical framework for pharmaceutical impurity control.

7967 records 8/532 page Previous Next First page 上5页 678910 下5页 Last page